4 results
The primary objective of this trial is to determine if EMD 1201081 (formerly known as IMO-2055) has anti-tumor activity in subjects by examining its effects on accepted clinical endpoints in combination with cetuximab. • To evaluate progression-free…
By adding Cetuximab to standard treatment, we hope to prolonge progression free survival
Our hypothesis is that continuous intravenous glucose monitoring is helpful in ICU patients treated with IIT to:a) reach and maintain the glucose-target of 4.4-6.1 mmol/L soonerb) to increase safety, by eliminating the development of hypoglycaemiac…
EFFICACY OBJECTIVESWithin each cohort, the study has the following co-primary efficacy objectives:· Assessing early efficacy during the Maintenance Treatment Phase based on a 20%reduction in tumour size after 2 months of treatment· Evaluating PFSThe…